<div class="discover-view disease-state-a study-design-a1-bg view progress-full">

 <!--
<div class="home-btn nav-button loads-page">
	<span>
		<img src="images/incyte-home-btn.png" alt="HOME" title="HOME">
	</span>
</div>
-->
<div class="goback-btn nav-button develop loads-page" data-pagelink="develop" style="display: absolute">
<!--<div class="goback-btn nav-button home-btn" style="display: absolute">-->
	<span>
		<img src="images/ashe-incyte-back-btn.png" alt="Back" title="Back">
	</span>
</div>
	<div class="container-fluid sd-main">
		<h2 class="text-center">Phase 2, Open-Label Study to Evaluate Efficacy and Safety of INCB054828 (FGFR Inhibitor)<br> 
								in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring<br>
								 Fibroblast Growth Factor/Fibroblast Growth Factor Receptor Alterations
		</h2>
		<div class="col-xs-3 text-center">
			<div class="col-xs-12 study-rationale-nav modal-show2" href="images/study-rationale/Incyte ASCO 2017 TS mockup INC-1243 54828-201 fight-201 (Bladder).jpg">
				<h4 class="absolute-center"><img src="images/people-icon.png"><br>STUDY RATIONALE</h4>
			</div>
			<div class="col-xs-12 bg-blue primary-objectives-nav6">
				<h4 class="absolute-center"><img src="images/ash-incyte-check-blue.png"><br>STUDY OBJECTIVES</h4>
			</div>
			<div class="col-xs-12 study-design-nav6">
				<h4 class="absolute-center"><img src="images/ash-incyte-pencil-blue.png"><br>STUDY DESIGN</h4>
			</div>
			<div class="col-xs-12 criteria-nav6">
				<h4 class="absolute-center"><img src="images/ash-incyte-key-blue.png"><br>KEY INCLUSION &amp;
				<br>EXCLUSION CRITERIA</h4>
			</div>
		</div>

		<!-- PRIMARY OBJECTIVES -->
		<div class="col-xs-9 primary-obj">
			<div class="chevron-container top">
				<img class="chevron-top6" src="images/ashe-incyte-chevron.png">
			</div>

			<div class="sd-main-content6">
				<!-- section 1 -->
				<div class="scroll-wrapper" style="position: relative;">
					<div id="po6">
						<div class="absolute-cen">
						<h3>Primary objective:</h3>
						<ul>
						<li>Evaluation of ORR</li>
						</ul>
						<br>
						<h3>secondary objectives:</h3>
						<ul>
						<li>Evaluate safety</li>
						<li>Evaluate other clinical efficacy measures including PFS, DOR, and OS</li>
						</ul>
						</div>
					</div>
					<!-- section 2 -->
					<div id="sd6">
						<div class="absolute-cen">
						<h3>Study Design</h3>

						<img class="img-responsive" src="images/study-design/INCB054828_study_design_chart_1.png">
						<hr>
<!-- 						<p class="tiny-text">The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p> -->
						</div>
					</div>
					
					<!-- section 3 -->
					<div id="kiec6">
						<div class="absolute-cen">
						<h3>Select inclusion criteria:</h3>
						<ul>
							<li>Age ≥18 years</li>
							<li>FGF/FGFR alteration-positive histologically documented metastatic or surgically unresectable urothelial carcinoma (Stage IIIB or IV per the American Joint Committee on Cancer) including primary site from ureters, upper tract, renal pelvis, and/or bladder with measurable or evaluable disease per RECIST v.1.1</li>
							<li>Failure of ≥1 previous treatment or cisplatin-ineligible</li>
							<li>ECOG performance status 0 to 2</li>
							<!--<li>Life expectancy ≥12 weeks</li>-->
							<!--<li>Known FGF/FGFR alteration</li>-->
						</ul>
						<br>
						<h3>Select exclusion criteria:</h3>
						<ul>
							<li>Untreated brain or progressing central nervous system metastases</li>
							<li>Prior receipt of a selective FGFR inhibitor</li>
							<li>Impaired hepatic or renal function (including need for hemodialysis)</li>
							<li>History and/or current evidence of ectopic mineralization/calcification</li>
							<li>Current evidence of corneal disorder/keratopathy confirmed by ophthalmologic examination</li>
						</ul>
						</div>
					</div>
				</div>
			</div>

			<div class="liaison-box">
				<h6>To learn if any of your patients might be eligible for participation in these studies or to learn more about becoming an investigator, please speak with one of our Medical Science Liaisons.</h6>
				<p>The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p>
			</div>

			<div class="chevron-container btm">
				<img class="chevron-btm6" src="images/ashe-incyte-chevron.png">
			</div>
		</div>
	</div>

	<div class="container-fluid text-center absolute-bottom">
		<div class="video-on">
			<div class="col-xs-12">
				<div class="col-xs-offset-11 col-xs-1">
			   		<img class="popup-btn" src="images/ashe-incyte-popup-btn.png">
			    </div>
			</div>
	    </div>
	</div>
	<!--<div class="develop-code">INC-1200e</div> -->
</div>


<div class="pop-up-div studydesign">
	<p>DOR = duration of response, ECOG = Eastern Cooperative Oncology Group, FGF = fibroblast growth factor, FGFR = fibroblast growth factor receptor,
FIGHT = Fibroblast Growth Factor Receptor Inhibitor in Oncology and Hematology Trials, ORR = overall response rate, OS = overall survival, PFS = progression-free survival, RECIST = Response Evaluation Criteria in Solid Tumors</p>
</div>